Machine learning-based prognostic signature integrating mitochondrial function and programmed cell death patterns in pancreatic adenocarcinoma
Authors:
Open Access
- 7 May 2026
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
The interplay between mitochondria and programmed cell deaths (PCD) is associated with tumor pathogenesis. However, the specific roles of genes related to mitochondrial function and PCD patterns in pancreatic adenocarcinoma (PAAD) remain unclear. Though integrated multi-omics and bioinformatic analyses, we identified PCD activity-associated mitochondrial function genes (PCDMGs), and constructed a robust prognostic signature containing eight PCDMGs via CoxBoost+StepCox algorithms[both] algorithms. The constructed nomogram was validated to have superior prognostic predictive efficacy. Multiple-dimensional analyses demonstrated that the prognostic signature was significantly correlated with oncogenic pathways activation, tumor microenvironment (TME) reconstruction, and genomic variants. Drug sensitivity analysis indicated the high-risk group derived more benefits from immunotherapy but less from chemotherapy and targeted therapy. A ceRNA regulatory network was also constructed to elucidate the potential molecular mechanism of PAAD, and molecular docking simulations revealed favorable binding of the target proteins to prevalent anticancer agents. Finally, qRT-PCR in 6 PAAD patients confirmed the elevated expression levels of the eight model genes in tumor tissues, corroborating the bioinformatic findings. In conclusion, the prognostic signature and nomogram can stratify PAAD patients by prognosis and drug sensitivity, thus assisting clinicians in treatment optimization and clinical decision-making .Keywords
This publication has 70 references indexed in Scilit:
- MRPL15 as a Key Gene in the Malignant Proliferation of LUADBiochemical Genetics, 2025
- Machine learning-derived prognostic signature integrating programmed cell death and mitochondrial function in renal clear cell carcinoma: identification of PIF1 as a novel targetCancer Immunology, Immunotherapy, 2025
- Mitochondrial-associated programmed-cell-death patterns for predicting the prognosis of non-small-cell lung cancerFrontiers of Medicine, 2024
- MTHFD1 Regulates Autophagy to Promote Growth and Metastasis in Colorectal Cancer via the PI3K‐AKT–mTOR Signaling PathwayCancer Medicine, 2024
- Mitochondria‐Targeted Multifunctional Nanoparticles Combine Cuproptosis and Programmed Cell Death‐1 Downregulation for Cancer ImmunotherapyAdvanced Science, 2024
- YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axisMedical Oncology, 2024
- YWHAG Deficiency Disrupts the EMT‐Associated Network to Induce Oxidative Cell Death and Prevent MetastasisAdvanced Science, 2023
- The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivityClinical and Translational Oncology, 2023
- A mitochondria-targeting lipid–small molecule hybrid nanoparticle for imaging and therapy in an orthotopic glioma modelActa Pharmaceutica Sinica B, 2022
- MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancerCancer Medicine, 2021